Name
CLOPIDOGREL
Mode of Action
IT IS AN ANALOGUE OF TICLOPIDINE,GIVEN PROPHYLACTICALLY AS AN ALTERNATIVE TO ASPIRIN. CLOPIDOGREL BISULFATE IS AN INHIBITOR OF ADP-INDUCED PLATELET AGGREGATION ACTING BY DIRECT INHIBITION OF ADENOSINE DIPHOSPHATE (ADP) BINDING TO ITS RECEPTOR AND OF THE SUBSEQUENT ADP-MEDIATED ACTIVATION OF THE GLYCOPROTEIN GPIIB/IIIA COMPLEX. IT CAUSES DOSE DEPENDENT INHIBITION OF PLATELET AGGREGATION AND RELEASE OF PLATELET GRANULE CONSTITUENTS AND PROLONGATION OF BLEEDING TIME. IT ALSO INHIBITS PLATELET ADRENALINE AND PLATELET ACTIVATING FACTOR.
Dosage
THE USUAL DOSE :- 75 MG ONCE DAILY. ACUTE CORONARY DISEASE: INITIALLY 300 MG THEN 75 MG DAILY
Drug Group
[ADP-INHIBITOR] , [ANTIPLATELET] , [PLATELET AGGREGATION INHIBITOR] , [TICLOPIDINE ANALOGUE] , [PLATELET ACTIVATION & AGGREGATION INHIBITOR] , [P2Y12 RECEPTOR BLOCKER] , [ADENOSINE DIPHOSPHATE RECEPTOR BLOCKER] , [THIENOPYRIDINES]
Cross Reaction
RISK OF HAEMORRHAGE, GASTRIC BLEED INCREASED WITH ASPIRIN, NSAID AND ORAL ANTICOAGULANTS. INCREASE IN PLASMA LEVEL OF CLOPIDOGREL WITH CIMETIDINE. INCREASE IN THEOPHYLLINE HALF-LIFE AND DECREASES PLASMA DIGOXIN LEVELS.
Drug Interaction
Drugs Side Effect
Drug Categories
Special Precaution
Drug Safety
Monograph